Aug 2026· Frontiers in Neurology· Vol 17· 0 citations· 71 references
Medicine
TL;DR
MEAF demonstrated favorable classification performance and interpretability in retrospective multicenter datasets, suggesting its potential as an auxiliary framework for multimodal assessment of AD-related cognitive staging.
Abstract
Objectives Alzheimer’s disease (AD) is the most prevalent type of neuro-degenerative dementia. Artificial intelligence assisted clinical evaluation can improve diagnostic efficiency and facilitate timely intervention. Methods An interpretable Multimodal Ensemble Assessment Framework (MEAF) was developed to support clinical evaluation for AD across the cognitive spectrum. This framework employed a Swin Transformer and ResNet-50 for staged modeling of imaging features, applied machine learning techniques to extract clinical features, and used decision-level ensemble learning to integrate multimodal predictions. For interpretability analysis, Gradient-weighted Class Activation Maps were used to highlight key brain regions contributing to imaging-based decisions, and Shapley Additive exPlanations were applied to quantitatively assess the importance of clinical features. Results MEAF achieved robust performance in classifying cognitively normal, mild cognitive impairment, and AD, with an accuracy of 0.878 and an F1-score of 0.877. In the independent external validation cohort, MEAF maintained reasonable performance, with an accuracy of 0.817 and an F1-score of 0.803. Interpretability analyses provided complementary explanations for both the imaging and clinical models. Conclusion MEAF demonstrated favorable classification performance and interpretability in retrospective multicenter datasets, suggesting its potential as an auxiliary framework for multimodal assessment of AD-related cognitive staging.
The results suggest that combining EEG data with clinical and demographic information can improve the accuracy of AD and FTD diagnosis, providing a promising tool for early detection.
A. Seçkin, Fatih Soygazi· Neural computing & applicati...· 0 citations
The findings support the potential role of structural MRI biomarkers combined with interpretable ML approaches for the classification of cognitive impairment and the integration of demographic variables improved model performance, particularly in binary discrimination tasks, whereas multiclass classification remained m...
Objective Alzheimer's disease (AD), the most common neurodegenerative disorder, is a leading cause of cognitive impairment and dementia in older adults. This study aimed to develop an interpretable machine learning model using multimodal MRI radiomics for the diagnosis of Alzheimer's disease. Materials and methods A to...
Nuerbiya Keranmu, Dilireba Aizezi, Xing-Yong Pan et al.· Frontiers in Aging Neuroscie...· 0 citations
Identifying progressive dementia during its prodromal stage is a challenging yet critical task for healthcare providers. Traditional clinical assessments are often not sensitive enough to detect warning signs of cognitive decline. Machine learning (ML) methods have shown promise in modeling clinical trajectories associ...
A. Gautier, L. Zheng, B. Schreurs· medRxiv· 0 citations
Alzheimer’s disease has been difficult to diagnose early because structural changes in the brain often appear subtle and overlap with normal aging. This study aimed to improve the accuracy and interpretability of Alzheimer’s disease detection from structural magnetic resonance imaging by developing a classification fra...
Kelvin Leonardi Kohsasih, Robet Robet, Johanes Terang Kita Perangin Angin et al.· Jurnal Informatika· 0 citations
Summary Accurate identification of Alzheimer’s disease (AD) stages is important for improving clinical understanding and supporting early-stage assessment. In this study, two multimodal MRI fusion strategies were developed to integrate structural MRI, resting-state functional MRI, and diffusion tensor imaging for pairw...
Chao-Qi Lv, Tao Liu, Hui-Juan Chen et al.· iScience· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.